Clinical Pharmacist And Nursing Roles In Managing High-Alert Medications In Emergency Departments: A Systematic Review
Abstract
Background: High-alert medications pose a significant risk of patient harm when mismanaged, particularly in Emergency Departments (EDs), where time-sensitive decisions and high workload increase the likelihood of medication errors. Clinical pharmacists and emergency nurses play critical and complementary roles in mitigating these risks through dose verification, medication preparation, administration, and patient monitoring. However, the extent of their collaboration and its impact on medication safety outcomes remain insufficiently explored.
Aim: This systematic review aims to synthesize current evidence on the roles of clinical pharmacists and emergency nurses in managing high-alert medications within EDs, and to examine how interprofessional collaboration influences medication safety and workflow efficiency.
Methods: Following PRISMA 2020 guidelines, a comprehensive search was conducted across PubMed, Scopus, Web of Science, CINAHL, and Google Scholar for studies published between 2010 and 2025. Eighteen studies met the inclusion criteria and were analyzed through narrative synthesis. Quality appraisal was performed using the Newcastle–Ottawa Scale, CASP, and JBI tools.
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.